Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR in Patients with Non-Cancer Pain

Progenics Pharmaceuticals, Inc. PGNX and Salix Pharmaceuticals, Ltd. SLXP today announced that the U.S. Food and Drug Administration has accepted for filing a supplemental New Drug Application for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection to treat opioid-induced constipation in patients with non-cancer pain. The FDA has issued an action date of April 27, 2012 under the Prescription Drug User Fee Act .